Kidney Week

Oral Abstract Session

Glomerular Targeted Therapies: The New Era

November 08, 2025 | 04:30 PM - 06:00 PM

Location: Room 310A, Convention Center

Session Description

Oral Abstract Session

Note: Continuing education credits are not being offered for this session.

Learning Pathway(s)

• Glomerular Diseases

Moderators

• Rupali S. Avasare, MD
• Vimal K. Derebail, MD, MPH, FASN

Presentations

• TRPC6 Inhibition for the Treatment of FSGS: Phase 2 Randomized Controlled Trial of BI 764198
  04:30 PM - 04:40 PM
  
  • Nicholas Cross, MBChB, PhD

TRPC6 Inhibition for the Treatment of FSGS: Phase 2 Randomized Controlled Trial of BI 764198

November 08, 2025 | 04:30 PM - 04:40 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Duration of Absolute Proteinuria Response with Nefecon in Patients with Primary IgAN: Results from the Two-Year NefIgArd Trial
  04:40 PM - 04:50 PM
  
  • Brad Rovin, FASN

Duration of Absolute Proteinuria Response with Nefecon in Patients with Primary IgAN: Results from the Two-Year NefIgArd Trial

November 08, 2025 | 04:40 PM - 04:50 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Pegcetacoplan for 52 Weeks Results in Sustained Proteinuria Reduction to Remission (≤0.5 g/g) and Normalization (≤0.2 g/g): Phase 3 VALIANT Trial
  04:50 PM - 05:00 PM
  
  • Carla M. Nester, MD, MS, FASN

Pegcetacoplan for 52 Weeks Results in Sustained Proteinuria Reduction to Remission (≤0.5 g/g) and Normalization (≤0.2 g/g): Phase 3 VALIANT Trial

November 08, 2025 | 04:50 PM - 05:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Ravulizumab in Atypical Hemolytic Uremic Syndrome: Time-to-Treatment Analysis from a Phase 3 Trial
  05:00 PM - 05:10 PM
  
  • Katherine Garlo, MD

Ravulizumab in Atypical Hemolytic Uremic Syndrome: Time-to-Treatment Analysis from a Phase 3 Trial

November 08, 2025 | 05:00 PM - 05:10 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Prospective Randomized Controlled 96-week Study to Evaluate the Efficacy and Safety of Tacrolimus and Glucocorticoid as Continuous Induction-Maintenance Treatment for Class III/IV±V Lupus Nephritis
  05:10 PM - 05:20 PM
  
  • Tak Mao Daniel Chan, MD, FASN

Prospective Randomized Controlled 96-week Study to Evaluate the Efficacy and Safety of Tacrolimus and Glucocorticoid as Continuous Induction-Maintenance Treatment for Class III/IV±V Lupus Nephritis

November 08, 2025 | 05:10 PM - 05:20 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Zanubrutinib (zanu) in Anti-Phospholipase A2 Receptor (PLA2R)-Associated Primary Membranous Nephropathy (PMN): Preliminary Results of a Phase 2/3, Multicenter, Randomized, Open-Label Study
  05:20 PM - 05:30 PM
  
  • Richard A. Lafayette, MD

Zanubrutinib (zanu) in Anti-Phospholipase A2 Receptor (PLA2R)-Associated Primary Membranous Nephropathy (PMN): Preliminary Results of a Phase 2/3, Multicenter, Randomized, Open-Label Study

November 08, 2025 | 05:20 PM - 05:30 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Targeting Podocytopathy: Liraglutide Restores Podocyte Adhesion Homeostasis via GLP1R-CD151-Dependent Integrin Signaling in FSGS
  05:30 PM - 05:40 PM
  
  • Ying Fan, MD, PhD

Targeting Podocytopathy: Liraglutide Restores Podocyte Adhesion Homeostasis via GLP1R-CD151-Dependent Integrin Signaling in FSGS

November 08, 2025 | 05:30 PM - 05:40 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• FB-7013: A Novel, Long-Duration siRNA Targeting Mannan-Binding Lectin Serine Protease 2 (MASP2) Exhibits Therapeutic Potential for Treatment of IgAN
  05:40 PM - 05:50 PM
  
  • Michael Zhiyan Wang, PhD

FB-7013: A Novel, Long-Duration siRNA Targeting Mannan-Binding Lectin Serine Protease 2 (MASP2) Exhibits Therapeutic Potential for Treatment of IgAN

November 08, 2025 | 05:40 PM - 05:50 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Spatially Controlled Immunosuppression with SynNotch T Cells for the Treatment of Kidney Autoimmunity
  05:50 PM - 06:00 PM
  
  • Tobias Eckey, MS

Spatially Controlled Immunosuppression with SynNotch T Cells for the Treatment of Kidney Autoimmunity

November 08, 2025 | 05:50 PM - 06:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.